


Ellerston JAADE Australian Private Assets Fund (Retail)



Investor Newsletter, April 2025

Investment Strategy		Performance Summary							
The Fund, through its investment in units in the Underlying Fund, invests in high growth private companies. The portfolio will be relatively concentrated and will aim to target between 10% – 20% of the Underlying Fund's NAV per investment across up to 12 Investee companies beyond the Initial Holding Period. Investee companies should have a minimum of \$10m in annual revenue and target growth of at least 20%.		Performance	3 Months	6 Months	1 Year	3 Years (p.a.)	4 Years (p.a.)	5 Years (p.a.)	Since Inception (p.a.)
		Retail^	2.25%	3.90%	10.81%	8.23%	12.03%	12.60%	16.05%**
		Strategy*	2.36%	4.19%	11.41%	8.67%	12.55%	13.26%	14.89%^
		^ Net return of the Ellerston JAADE Australian Private Assets Fund (Retail) ("Fund") as at 31 March 2025. * Net return on the Ellerston JAADE Australian Private Assets Fund (Wholesale) ("Underlying Fund"), in which the Fund is invested. ** Fund inception is 5 July 2019. Since inception performance is calculated from 30 September 2019, which is the date from which the Fund made its first investment into the Underlying Fund.							
Investment Team		Portfolio Companies							
Jamie Odell • David Leslie • Antonia Korsanos • Anthony Klok • Jayne Shaw • Justin Diddams • Michael Calabrese • Geronimo Cieza • Jason Martin • John Parathyras		SiteMinder Initial Investment: December 2019 Cost of Current Exposure: \$15m Current Fair Value: \$15m* Securities: Ordinary Shares Industry Focus: Travel/Accommodation Business Model: SaaS Board Representative: N/A							
Key Information		Company Overview							
Fund Inception**		SiteMinder (ASX: SDR) is the world's leader hotel commerce platform with 41,600+ Properties and \$70bn+ in Gross Booking Value. The core products simultaneously connect hotels to booking websites and other distribution channels, enabling hotels to manage their inventory. It operates a subscription-as-a-service (SaaS) business model for clients. SiteMinder has grown to be the #1 hotel acquisition platform globally, with 41k+ subscription properties in +150 countries; with 9 offices, 850+ staff operating in 20+ countries serving 11 languages.							
Strategy Inception^									
Structure									
Strategy FUM*									
NAV Price^									
Pricing									
Management Fee (p.a.)									
Performance Fee									
Hurdle Rate									
Distribution									
* includes capital inflows effective the end of the most recent quarter ^ NAV mid-price (post distribution)									
Research		Investment Thesis							
Zenith' (Rating: Recommended)		SiteMinder is the market leading player in the channel management segment with a global sales footprint. There's one million potential customers in its target addressable market which represents a material opportunity to increase its penetration. Furthermore, SiteMinder is also building additional tools and applications for hotels to increase its share of spend in the segment.							
Platforms		* Carrying value as of 31 Mar 2025 (\$4.37 share price; cost of current exposure avg. share price at \$4.24).							
Asgard, Ausmaq, Panorama, BT Wrap, Hub24, Macquarie Wrap, Netwealth, Powerwrap, XPlore Wealth, Morgan Stanley, uXchange		riskconnect. Integrated Risk Management Solutions™							
		Initial Investment: May 2024 Invested Amount: \$7m Current Fair Value: \$7m Securities: Ordinary Shares Industry Focus: Risk Management Business Model: SaaS Board Representative: N/A							
		Company Overview							
		Riskconnect is a leading Integrated Risk Management platform provider owned by PE firms TA Associates and Thoma Bravo. The company's platform provides clients with a single view from which to manage operational, strategic and digital risk.							
		Investment Thesis							
		Riskconnect management team expects to use Camms' acquisition to expand its geographical presence into APAC (only 5% of its current revenue come from APAC) and cross sell its products across both businesses. The business has a history of growing through M&A complementing organic initiatives and has maintained high employee retention after these acquisitions.							



Initial Investment: February 2019
Invested Amount: \$16m
Current Fair Value: \$99m
Securities: Ordinary Shares

Industry Focus: Disability and Aged Care
Business Model: Marketplace for Carers
Board Representative: Jayne Shaw, David Leslie

Company Overview

Mable is the leading marketplace platform for the "Home Care" sector, across both aged care and disability segments in Australia, connecting consumers with care workers. The key tailwind in the sector has been the shift in government policy to consumer directed spending and away from funding grants to care provider organisations. This shift means consumers and their families are actively looking for better value and personalised support, making Mable's platform appealing to a growing audience.

Investment Thesis

Mable has a first mover advantage in the provision of marketplace services for the aged care and disability sectors. The platform is leveraging technology to disrupt the traditional delivery of services by care providers in Australia. Total addressable market for the platform is \$33bn (Disability Support \$25bn + Aged Home Care \$8bn), out of which Mable has less than 1% penetration.

Prospecta

Initial Investment: November 2020
Invested Amount: \$26m
Current Fair Value: \$34m
Securities: Preference Shares, Convertible Notes

Industry Focus: Industrial Companies
Business Model: Enterprise Software
Board Representative: Anthony Klok (Alternate: Justin Diddams)

Company Overview

Prospecta is a leading provider of data governance and master data management for enterprise clients, via its Master Data Online (MDO) platform, which is certified by both SAP and Salesforce. MDO's modules cover master data governance, data quality, supply chain logistics, workforce safety and partner collaboration. The business has a global blue-chip customer base, and is viewed as a domain expert in master data management, operating in a global addressable market of SAP clients, which face increasingly complex ERP environments.

Investment Thesis

The quality and control of data is gaining increasing importance amongst enterprises, particularly on the supply side. Prospecta's MDO modules cover master data governance, data quality, supply chain logistics, workforce safety and partner collaboration.

Phocas.

Initial Investment: December 2020
Invested Amount: \$37m
Current Fair Value: \$75m
Securities: Preference Shares, Convertible Notes

Industry Focus: Business / Data Analytics
Business Model: Enterprise Software
Board Representative: Toni Korsanos (Alternate: David Leslie)

Company Overview

Phocas is a leading cloud-based SaaS BI software specialising in business intelligence and data analytics for mid-market customers in the Distribution, Manufacturing and Retail sectors. The Company has a diverse customer base of +2,700 clients across countries and industries, with majority annual recurring subscription revenue.

Investment Thesis

Company is well positioned to deliver continued growth; via new products and features, expanding its partnerships with ERPs and exploiting its existing international footprint in the US and UK (which represent +70% of revenue).



Initial Investment: August 2021
Invested Amount: \$17m
Current Fair Value: \$25m
Securities: Preference Shares, Convertible Notes

Industry Focus: Financial Services
Business Model: Payment Platform
Board Representative: Justin Diddams

Company Overview

Azupay is an emerging payment service provider enabling consumers, businesses and government to make and receive instant and safe payments on a 24/7 basis from a bank account without the need for a debit or credit card. The Company's products are built on the New Payments Platform (NPP), recently launched as a modern alternative to existing payment methods like card schemes, BPAY and direct entry.

Investment Thesis

Against the backdrop of a regulatory-led shift to digital payments, Azupay is well positioned to leverage its first mover advantage in the real-time payments market. The Company's technology is built and operational with clear user benefits over legacy methods and has an experienced management team capable of helping the Company deliver on its robust growth forecasts.



Initial Investment: September 2021
Invested Amount: \$35m
Current Fair Value: \$17m
Securities: Preference Shares, Convertible Notes

Industry Focus: Healthcare
Business Model: SaaS
Board Representative: Jayne Shaw

Company Overview

Prospection provides Real World Evidence (RWE) empowering pharma companies and health care providers to make data-driven decisions. The Company uses complex health and pharma data, combined with its proprietary algorithms, to generate insights into patient outcomes across various diseases and treatments. Its subscription cloud based platform follows millions of de-identified patients over time to search for patterns in the health and treatment journey, and improve clinical outcomes

Investment Thesis

Global pharma companies are increasingly turning to RWE to drive clinical and commercial use cases, while improving time and cost efficiencies. Prospection serves 17 of the Top 20 Global Pharma companies, and its foundation clients have been a significant driver of the business, pushing the business into new international markets.



Initial Investment: April 2023
Invested Amount: \$22m
Current Fair Value: \$32m
Securities: Managed Equity

Industry Focus: Business Productivity
Business Model: SaaS
Board Representative: N/A

Company Overview

Nitro's Document Productivity Platform includes powerful PDF editing tools, digital workflows, highly secure eSigning and identity verification capabilities, which competes with tier-1 providers Adobe and DocuSign. Nitro has over 2.8 million licensed users and 14,000+ business customers across 179 countries, including over 62% of the Fortune 500.

Investment Thesis

Huge Greenfield opportunities in the SMB space: only 11% of SMBs use PDF editors (vs. 86% of Enterprise businesses). Tailwinds from companies shifting processes to online to drive more efficient processes and acceptance of eSignatures. The company is viewed as a better one-stop-shop solution (PDF productivity and eSignature), at a lower-price point (20-50% cheaper) and better customer service than peers.

data zoo

Initial Investment: April 2024
Invested Amount: \$40m
Current Fair Value: \$40m
Securities: Preferred Equity & Convertible Notes

Industry Focus: Regulation & Compliance
Business Model: ID Verification Platform
Board Representative: Anthony Klok

Company Overview

Data Zoo is a global ID verification platform with blue-chip customers such as Stripe, PayPal, MoneyGram and eToro among others. Data Zoo's verification software provides direct access to data from 170+ countries, enhancing KYC/KYB compliance and fraud prevention, while emphasising data privacy & protection by eliminating identity data storage. With over 150 clients and a diverse mix of revenue across US, Europe, Asia and Australia, the business has now established itself as a credible alternative to incumbent ID verification services.

Investment Thesis

ID Verification is a large (\$20bn TAM) and fast-growing (+23% CAGR) market driven by a growing need to KYC clients with greater accuracy and ease, as well as reducing fraud. The primary capital will give the Company additional firepower to pursue new growth initiatives, upgrade the operational executives and continue to integrate the latest and deepest data sources and capabilities around ID verification.



Initial Investment: October 2024
Invested Amount: \$32m
Current Fair Value: \$32m
Securities: Preferred Equity

Industry Focus: MedTech
Business Model: Marketplace / Regulatory Platform
Board Representative: David Leslie

Company Overview

FreshClinics is a capital-lite business that provides an end-to-end solution for democratizing clinic startup and ownership. Fresh provides numerous resources such as Electronic medical records platform, an operating platform, legal advice, free training, and more to generate savings and cheaper medical oversight.

Investment Thesis

Fresh has resonated in the Australian market, with around 14% share of 9.2k clinics in < 5 years. As they plan to expand to the US, they are tapping into a large and fast-growing medical aesthetics market, with a TAM of US\$5bn and 10% growth p.a. in volume terms due to trends in the aging population and rise of social media fuelling demand.

Contact Us

Sydney

Level 11, 179 Elizabeth Street,
Sydney, NSW 2000
+612 90217701
info@ellerstoncapital.com

Find out more

Should investors have any questions or queries regarding the Fund, please contact our Investor Relations team on **02 9021 7701** or info@ellerstoncapital.com or visit us at ellerstoncapital.com.

All holding enquiries should be directed to our registry, APEX Fund Services on **1300 133 451** or registry@apexgroup.com & Ellerston@apexgroup.com.

The Zenith Investment Partners Pty Ltd ("Zenith") Australian Financial Services License No. 226872 rating (assigned 31 January 2021) referred to in this document is limited to "General Advice" (as defined by the Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the Product Disclosure Statement or offer document, and Target Market Determination, before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Zenith usually charges the product issuer, fund manager or a related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessment's and at www.zenithpartners.com.au.

This report has been prepared by Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000, as the responsible entity of the Ellerston JAADE Australian Private Assets Fund (Retail) ARSN 634 091 875 without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision about the Fund persons should read the Fund's Product Disclosure Statement and Target Market Determination (TMD) which can be obtained from the Manager's website www.ellerstoncapital.com or by contacting info@ellerstoncapital.com and obtain advice from an appropriate financial adviser. Units in the Fund are issued by Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000. This information is current as at the date on the first page.

This material has been prepared based on information believed to be accurate at the time of publication. Assumptions and estimates may have been made which may prove not to be accurate. Ellerston Capital undertakes no responsibility to correct any such inaccuracy. Subsequent changes in circumstances may occur at any time and may impact the accuracy of the information. To the full extent permitted by law, none of Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000, or any member of the Ellerston Capital Limited Group of companies makes any warranty as to the accuracy or completeness of the information in this newsletter and disclaims all liability that may arise due to any information contained in this newsletter being inaccurate, unreliable or incomplete. Past performance is not a reliable indicator of future performance.